- Home
- ANVS vs OVID Comparison
ANVS vs OVID Comparison
Compare ANVS & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANVS | OVID |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.3M | 117.5M |
| IPO Year | 2019 | 2017 |
Fundamental Metrics
Financial Performance| Metric | ANVS | OVID |
|---|---|---|
| Price | $2.69 | $1.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $13.50 | $3.40 |
| AVG Volume (30 Days) | 354.2K | ★ 1.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.92 | 3.90 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $566,000.00 |
| Revenue This Year | N/A | $1,077.56 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.11 | $0.24 |
| 52 Week High | $5.50 | $2.01 |
Technical Indicators
Market Signals| Indicator | ANVS | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 48.70 | 53.68 |
| Support Level | $2.27 | $1.43 |
| Resistance Level | $2.97 | $1.70 |
| Average True Range (ATR) | 0.20 | 0.10 |
| MACD | 0.07 | 0.02 |
| Stochastic Oscillator | 55.50 | 82.26 |
Price Performance
Historical ComparisonAbout ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.